Related Experiment Video
Updated: Jun 19, 2025

07:20
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
1.1K
Improving Spasticity by Using Botulin Toxin: An Overview Focusing on Combined Approaches
Loredana Raciti1, Gianfranco Raciti2, Antonio Ammendolia2
1Unità Spinale Unipolare, AO Cannizzaro, 98102 Catania, Italy.
Brain Sciences
|July 27, 2024
Summary
Combining botulinum toxin type A (BoNT-A) injections with physical therapy or robotic training effectively treats spasticity. This approach enhances patient outcomes, potentially reducing toxin dosage, side effects, and costs.
Area of Science:
- Neurology
- Rehabilitation Medicine
- Biotechnology
Background:
- Spasticity, a common neurological disorder, involves increased muscle tone and hypertonia, leading to limb deformities, pain, and impaired motor function.
- Current treatments include rehabilitation, oral medications like baclofen, and injectable therapies such as botulinum toxin type A (BoNT-A).
- BoNT-A injections are effective for spasticity, but often require combination with other therapies when insufficient alone.
Purpose of the Study:
- To review the efficacy of combining pharmacological or non-pharmacological treatments with BoNT-A injections for managing spasticity.
- To evaluate the benefits of adjunct therapies, including conventional physical therapy and robotic-assisted training, when used with BoNT-A.
Main Methods:
- Systematic review of studies investigating combined treatment strategies for spasticity.
- Analysis of outcomes from therapies integrating BoNT-A with physical therapy, robotic gait training, or other adjunct activities.
- Focus on studies involving end-effector robotic systems.
Main Results:
- Combination therapy of BoNT-A with conventional physical therapy or robotic training shows positive effects on patient activity levels and upper limb function, even in chronic stroke patients.
- Combined strategies may potentiate the effects of BoNT-A, allowing for reduced dosages.
- This integrated approach offers a valid method for improving patient performance and overall outcomes.
Conclusions:
- Combined therapeutic strategies involving BoNT-A injections and rehabilitation (physical therapy or robotics) are effective for spasticity management.
- These combined approaches can enhance treatment efficacy, potentially leading to lower botulinum toxin dosages, reduced side effects, and decreased healthcare costs.
- The integration of BoNT-A with advanced rehabilitation techniques like robot-assisted training represents a promising avenue for improving patient quality of life.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
664
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
664
Skeletal Muscle Relaxants: Therapeutic Uses
477
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
477
Spasmolytic Agents: Chemical Classification
874
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
874

